We met with Dr Amy E Rothberg (Associate Professor, School of Public Health, University of Michigan, Ann Arbor, MI, US) at the ADA 2018 meeting to discuss the OPTIWIN study and OPTIFAST program. The OPTIWIN study was a randomized controlled trial which compared the effectiveness of a meal-replacement program to a traditional food-based diet, on long-term relative weight loss and weight maintenance. The results showed that participants in the OPTIFAST program lost twice the amount of weight than those doing food-based dieting. In patients with diabetes, there were greater improvements in glycated hemoglobin, reductions in fasting glucose, and even the resolution of type 2 diabetes mellitus in the OPTIFAST group. Dr Rothberg also discusses the challenges she faces when treating obese patients with diabetes or prediabetes, and explains that they are often discouraged by failed weight-loss programs, and consequently opt for easier pharmaceutical options.
1. What was the background and rationale behind the OPTIWIN study? (0:13)
2. What were the key findings of the study presented at this meeting? (1:07)
3. What are the main challenges you face when treating obese patients with diabetes or prediabetes? (2:09)
Filmed at the American Diabetes Association (ADA) Annual Meeting, June 2018
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021 – Anticipated congress highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20-1:30) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!